

knowledgebank > [Projects](http://www.pharmafocusasia.com/projects) (<http://www.pharmafocusasia.com/projects>)

Vetter invests 300 million Euro to expand and upgrade its manufacturing facilities in Germany



Introduction:

Vetter has announced to invest approximately 300 million euros to expand and upgrade its manufacturing facilities over an estimated five-year period.

Features:

The upgrades are being driven by a changing healthcare market that is affected by issues such as ever-more complex molecules, smaller batch sizes, and increasing regulatory requirements.

The first of the facility expansions are already ongoing at several of the company's German locations including its 'Ravensburg Vetter West' center for visual inspection and logistics. Structural work for the facility enlargement, which will offer more than double of its current capacity, is completed with the site being on schedule to become fully operational in 2017.



In addition, the Ravensburg Vetter South production site has also been designated for significant enlargements as is the Ravensburg Schuetzenstrasse facility where initial construction activities began in 2013. All three site expansions will result in additional capacities for drug product manufacturing and logistic services.

A central technology element of the planned upgrades will be the implementation of an in-house made improved restricted access barrier system (RABS) concept which will contribute to increased operational excellence in aseptic manufacturing. To better meet future industry trends in quality, safety and flexibility, a corporate project team has evolved this 'Improved RABS concept' by combining the advantages of isolator and RABS technology. The core of the approach is a uniquely fast, by today's standards, 3-hour cycle and fully automated decontamination of the cleanroom using hydrogen peroxide (H₂O₂), resulting from an extremely high level of process innovation.

Specifications:

Company Name	Vetter
Location	Germany
Type	Expand & Upgrade Manufacturing Facilities
Estimated Cost	€300 million

All Rights Reserved

OCHRE-MEDIA PVT LTD ([HTTP://OCHRE-MEDIA.COM](http://ochre-media.com))

[ABOUT US \(HTTP://WWW.PHARMAFOCUSASIA.COM/ABOUTUS\)](http://www.pharmafocusasia.com/aboutus)

[REGISTER \(HTTP://WWW.PHARMAFOCUSASIA.COM/REGISTRATION\)](http://www.pharmafocusasia.com/registration)

[TERMS & CONDITIONS \(HTTP://WWW.PHARMAFOCUSASIA.COM/TERMS-CONDITIONS\)](http://www.pharmafocusasia.com/terms-conditions)

[CONTACT US \(HTTP://WWW.PHARMAFOCUSASIA.COM/CONTACTUS\)](http://www.pharmafocusasia.com/contactus)

(https://www.linkedin.com/groups?home=&gid=6750706&trk=anet_ug_hm)

(<https://www.facebook.com/PharmaFocusAsia>) (<https://twitter.com/pharmafocusasia>)